SEC Company Response from Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328) (SBFM) — Feb 7, 2012
Sunshine Biopharma Inc. (SBFM, SBFMW) (CIK 0001402328)
Date: Feb. 7, 2012 · CIK: 0001402328 · Accession: 0001354488-12-000453
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-52898
Letter
VIA EDGAR ONLY Division of Corporate Finance United States Securities and Exchange Commission Sunshine Biopharma, Inc. Item 4.01 Form 8-K Filed on February 3, 2012 File No. 000-52898
Re:
Dear Mr. Lee:
In relation to the responses to the staff’s comment letter, above referenced, relating to the above referenced matter please be advised that:
(a) Sunshine Biopharma, Inc. (the “Issuer”) is responsible for the adequacy and accuracy of the disclosure in its filings, including, but not limited to, the above referenced filing;
(b) the staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filings; and
(c) we acknowledge that the Issuer may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yours very truly,
SUNSHINE BIOPHARMA, INC.
/s/ Steve Slilaty
Steve Slilaty
Chief Executive Officer
Show Raw Text
CORRESP
1
filename1.htm
sbfm_corresp.htm
February 6, 2012
VIA EDGAR ONLY
Mr. Wilson K. Lee
Division of Corporate Finance
United States Securities and Exchange Commission
Washington, D.C. 20549
Re:
Sunshine Biopharma, Inc.
Item 4.01 Form 8-K
Filed on February 3, 2012
File No. 000-52898
Dear Mr. Lee:
In relation to the responses to the staff’s comment letter, above referenced, relating to the above referenced matter please be advised that:
(a) Sunshine Biopharma, Inc. (the “Issuer”) is responsible for the adequacy and accuracy of the disclosure in its filings, including, but not limited to, the above referenced filing;
(b) the staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filings; and
(c) we acknowledge that the Issuer may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Yours very truly,
SUNSHINE BIOPHARMA, INC.
/s/ Steve Slilaty
Steve Slilaty
Chief Executive Officer